DrugInformations.org

In recent years, stem cell researchers have become very adept at manipulating the fate of adult stem cells cultured in the lab. Now, researchers at the Salk Institute for Biological Studies achieved the same feat with adult neural stem cells still in place in the brain. They successfully coaxed mouse brain stem cells bound to join the neuronal network to differentiate into support cells instead.

More: continued here

No Comments »

Regulated information UCB announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has issued a positive opinion recommending that the European Commission grants a marketing authorisation for lacosamide, proposed trade name Vimpat?, for the adjunctive treatment of partial onset seizures with or without secondary generalisation in patients with epilepsy, aged 16 years and older.

More: continued here

No Comments »

A drug discovery and development collaboration between leading Australian Institutions, the Children’s Medical Research Institute (CMRI), University of Newcastle, University of Melbourne and Bio-Link Partners Ltd., has been announced as the Epilepsy Therapy Project, June 2008 New Therapy Grant winners.

More: continued here

No Comments »

Researchers in Victoria, Australia have developed a new genetic test to help predict the response of epilepsy sufferers to commonly used drug treatments. The non-invasive blood-based test has been developed by doctors from the Royal Melbourne Hospital, Melbourne University and the Murdoch Children’s Research Institute.

More: continued here

No Comments »

UCB announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has issued a positive opinion recommending that the European Commission grants a marketing authorisation for lacosamide, proposed trade name Vimpat(TM), for the adjunctive treatment of partial onset seizures with or without secondary generalisation in patients with epilepsy, aged 16 years and older.

More: continued here

No Comments »

The most prestigious funding body in the world for epilepsy has financially backed Australian research into new approaches to treat the condition. The Epilepsy Therapy Project will provide almost US$300,000 over the next two years to a group of researchers from leading Australian institutions including the University of Newcastle.

More: continued here

No Comments »

Carnegie Mellon University neuroscientists have identified what may be the first known common denominator underlying inherited and sporadic epilepsy - a disruption in an ion channel called the BK channel. Although BK channels have been linked to a rare, familial form of epilepsy, their involvement in other types of seizure disorders has never been demonstrated.

More: continued here

No Comments »

People with epilepsy who fail to take their seizure medication regularly could be as much as three times more likely to die, according to a study published in the June 18, 2008, online issue of Neurology®, the medical journal of the American Academy of Neurology.For the study, researchers looked at insurance records from three U.S. state Medicaid programs over eight and a half years.

More: continued here

No Comments »

The Epilepsy Foundation honored the Medtronic Foundation for its ongoing dedication and determination to helping people with chronic neurological conditions. The award was presented by the Epilepsy Foundation’s president and CEO, Eric R. Hargis, during a ceremony at Medtronic’s world headquarters in Fridley, Minn.

More: continued here

No Comments »

Eisai Europe Limited, (Headquarters: London, Chairman and CEO Yutaka Tsuchiya) today announced publication of the results of a major study of its new anti-epileptic agent Inovelon (rufinamide) indicated for adjunctive therapy in Lennox-Gastaut Syndrome (LGS), a severe form of generalised epilepsy that develops in early childhood.

More: continued here

No Comments »